Fideuram Intesa Sanpaolo Private Banking S.P.A. Sells 166,156 Shares of Gilead Sciences, Inc. $GILD

Fideuram Intesa Sanpaolo Private Banking S.P.A. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,719 shares of the biopharmaceutical company’s stock after selling 166,156 shares during the quarter. Gilead Sciences accounts for about 1.2% of Fideuram Intesa Sanpaolo Private Banking S.P.A.’s portfolio, making the stock its 15th largest position. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Gilead Sciences were worth $34,525,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC grew its position in shares of Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GILD. Morgan Stanley lowered their price target on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Leerink Partners reduced their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Truist Financial reiterated a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Tuesday, June 16th. Finally, Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 83,000 shares of company stock worth $10,824,500. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Up 4.2%

Shares of NASDAQ GILD opened at $131.27 on Friday. The stock has a market capitalization of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. The company has a 50-day moving average price of $129.48 and a 200-day moving average price of $134.56. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.